PR Newswire Clinical TrialsOriginal article
Blood Cancer Treatment Allows Hard-to-Match Kidney Failure Patients to Receive a Compatible Kidney Transplant
Phase 1positiveCAR T cell therapyPositive
AI Analysis
Summary
NYU Langone-led Phase 1 trial demonstrates CAR T cell therapy successfully desensitizes hard-to-match kidney transplant candidates, with three patients now able to receive compatible kidney transplants. The novel approach addresses a significant challenge in transplantation for patients with end-stage kidney disease.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Patients
3
Outcome Details
Phase 1 trial successfully demonstrated CAR T cell therapy can safely desensitize challenging transplant candidates, enabling three patients with end-stage kidney failure to receive compatible kidney transplants
Importance:6/10
Sentiment:
0.80
CAR T cell therapykidney transplantationimmunodesensitizationclinical trialkidney failure
Read the original article
Published by PR Newswire Clinical Trials on June 3, 2026 9:00 PM